Gain Therapeutics Inc.

9.66-0.5000-4.92%Vol 43.04K1Y Perf -13.21%
Jun 14th, 2021 16:00 DELAYED
BID9.70 ASK9.80
Open10.29 Previous Close10.16
Pre-Market- After-Market-
 - -  - -%
Target Price
30.00 
Analyst Rating
— — 0.00
Potential %
210.56 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+ —    60.45
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap114.73M 
Earnings Rating
Price Range Ratio 52W %
9.91 
Earnings Date
-

Today's Price Range

9.5510.29

52W Range

8.7517.93

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
-9.30%
1 Month
0.52%
3 Months
-
6 Months
-
1 Year
-13.21%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GANX9.66-0.5000-4.92
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.13-0.50-284.62
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume43.04K
Shares Outstanding11.88M
Trades Count682
Dollar Volume0
Avg. Volume78.33K
Avg. Weekly Volume33.90K
Avg. Monthly Volume29.07K
Avg. Quarterly Volume78.33K

Gain Therapeutics Inc. (NASDAQ: GANX) stock closed at 9.66 per share at the end of the most recent trading day (a -4.92% change compared to the prior day closing price) with a volume of 43.04K shares and market capitalization of 114.73M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Gain Therapeutics Inc. CEO is Eric I. Richman.

The one-year performance of Gain Therapeutics Inc. stock is -13.21%, while year-to-date (YTD) performance is %. GANX stock has a five-year performance of %. Its 52-week range is between 8.75 and 17.93, which gives GANX stock a 52-week price range ratio of 9.91%

Gain Therapeutics Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 2.71, a price-to-sale (PS) ratio of 4 391.55, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -11.33%, a ROC of -11.92% and a ROE of -12.24%. The company’s profit margin is -%, its EBITDA margin is -19 737.30%, and its revenue ttm is $27.48 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Gain Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Gain Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Gain Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Gain Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gain Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Gain Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 53.10, ATR14 : 0.75, CCI20 : -127.80, Chaikin Money Flow : -0.14, MACD : -0.33, Money Flow Index : 34.33, ROC : -7.82, RSI : 36.33, STOCH (14,3) : 7.75, STOCH RSI : 0.00, UO : 35.64, Williams %R : -92.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gain Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Gain Therapeutics Inc.

Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.

CEO: Eric I. Richman

Telephone: +1 301 500-1556

Address: 4800 Hampden Lane, Bethesda 20814, MD, US

Number of employees: 16

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

News

Stocktwits